We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Sensitive, Reusable and Rapid Diagnostic Platform to Detect Multiple Pathogens

By LabMedica International staff writers
Posted on 15 Jun 2023
Print article
Image: The G-MAB library contains more than 10 quadrillion (1016) distinct antibody sequences (Photo courtesy of Sorrento)
Image: The G-MAB library contains more than 10 quadrillion (1016) distinct antibody sequences (Photo courtesy of Sorrento)

The development timeline for current rapid testing diagnostic devices (RTDs) is very lengthy, and their clinical sensitivity also tends to be low. Now, a new diagnostic platform is currently under development for rapid and sensitive detection of proteins and other biomolecules, thereby enhancing existing RTDs.

Sorrento Therapeutics (San Diego, CA, USA) and its wholly owned subsidiary, Virex Health (Boston, MA, USA) are jointly developing a highly sensitive, cost-effective diagnostic platform that is adaptable for various pathogens. This initiative harnesses Sorrento's expertise in rapidly selecting and producing highly specific antibodies from its proprietary G-MAB library that target viral and bacterial antigens. This process is combined with Virex’s novel chemical detection approach and utilizes the existing infrastructure of the glucometer industry. Sorrento’s proprietary G-MAB technology utilizes RNA transcription to amplify antibody variable domains from over 600 donors. Detailed analysis of deep sequencing DNA data reveals that the G-MAB library comprises over 10 quadrillion (1016) unique antibody sequences, making it one of the largest fully human antibody libraries in the biopharmaceutical industry.

Virex’s proprietary technology enables electrochemical detection of bioanalytes (such as viruses, proteins, and small molecules), which employs the same electronic devices required in reusable glucometers. The test strip chemistry has been reconfigured by Virex to detect pathogens. The aim is to cater to the needs of rapid detection for biodefense and preparation for emerging infectious diseases. Both Sorrento and Virex aim to provide a rapid, sensitive, accurate, and scalable diagnostic that can be swiftly deployed to combat an imminent or recurring threat.

“Once the diagnostic platform is developed, our unique approach can be quickly transferred to other pathogens and deployed when needed on a large scale,” said Scott Schaus, Ph.D., Co-founder and Chief Technology Officer for Virex Health.

Related Links:
Sorrento Therapeutics
Virex Health

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.